Condition: Oral Neoplasm · Sponsor: Proteocyte Diagnostics Inc.
The purpose of this observational study is to evaluate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in determining the risk of progression to cancer of clinically suspicious oral lesions.
This description comes directly from the study's public registry record.
Jason Hwang, PhD · (647) 255-1370 · jhwang@proteocyte.com
Mark Darling, MSc, MChD · (519) 661-2111 · mark.darling@schulich.uwo.ca
Always discuss trial participation with your own doctor first.
| Kingsway Oral & Maxillofacial Surgery | Edmonton, Alberta, Canada | Recruiting |
| University of Alberta | Edmonton, Alberta, Canada | Recruiting |
| Western University | London, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04622462